Editas Medicine Inc. (NASDAQ:EDIT) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

According to Zacks, “Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. “

Separately, Jefferies Group assumed coverage on shares of Editas Medicine in a research note on Thursday, June 2nd. They set a “hold” rating and a $35.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $33.50.

Analyst Recommendations for Editas Medicine (NASDAQ:EDIT)

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/editas-medicine-inc-edit-stock-rating-upgraded-by-zacks-investment-research.html

Shares of Editas Medicine (NASDAQ:EDIT) traded up 1.02% on Tuesday, hitting $14.90. 338,380 shares of the stock traded hands. The firm’s market capitalization is $527.52 million. Editas Medicine has a 52 week low of $12.57 and a 52 week high of $43.99. The firm’s 50 day moving average is $19.08 and its 200 day moving average is $28.64.

Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.54) EPS for the quarter, hitting the consensus estimate of ($0.54). On average, analysts expect that Editas Medicine will post ($2.59) EPS for the current fiscal year.

In other Editas Medicine news, major shareholder Polaris Venture Management Co. sold 500,000 shares of Editas Medicine stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $16.80, for a total value of $8,400,000.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Kevin P. Starr sold 5,890 shares of Editas Medicine stock in a transaction that occurred on Tuesday, September 6th. The shares were sold at an average price of $15.90, for a total transaction of $93,651.00. The disclosure for this sale can be found here.

A number of hedge funds and other institutional investors have recently made changes to their positions in EDIT. Royal Bank of Canada bought a new position in shares of Editas Medicine during the first quarter worth $164,000. Deerfield Management Co. bought a new position in shares of Editas Medicine during the first quarter worth $59,043,000. Barclays PLC bought a new position in shares of Editas Medicine during the first quarter worth $824,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Editas Medicine during the first quarter worth $336,000. Finally, Polaris Venture Management Co. VI L.L.C. bought a new position in shares of Editas Medicine during the first quarter worth $160,824,000. 61.00% of the stock is currently owned by hedge funds and other institutional investors.

Editas Medicine Company Profile

Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.

5 Day Chart for NASDAQ:EDIT

Get a free copy of the Zacks research report on Editas Medicine (EDIT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.